Oncoplastic Central Partial Mastectomy and Neoareolar Reduction Mammoplasty with Immediate Nipple Reconstruction: An Initial Report of a Novel Option for Breast Conservation in Patients with Subareolar Tumors
Breast-conserving therapy (BCT) has been associated with better quality of life and cosmetic outcomes than mastectomy. However, subareolar cancers abutting the nipple–areolar complex (NAC) present a unique cosmetic and oncologic challenge. Oncoplastic central partial mastectomy and neoareolar reduction mammoplasty with immediate nipple reconstruction is a novel technique that can permit BCT for these patients.
This study enrolled consecutive patients with central tumors during 2017–2018 who underwent central partial mastectomy reconstructed with neoareolar reduction mammoplasty and immediate nipple reconstruction. Patient demographics, imaging and pathology size, margin width, mastectomy and reexcision rates, and cosmesis were evaluated.
The study identified 23 sequential patients. The average patient age was 60.5 ± 12.3 years, and the average body mass index was 29.4 ± 5.7 kg/m2. The mean lesion size was 51.5 ± 43.0 mm on preoperative imaging, and the average disease span shown by the final pathology was 59.5 ± 45.3 mm. “No ink on tumor” was achieved for 22 patients (95.7%). In 13 patients (56.5%), the margins were inadequate for ductal carcinoma in situ (DCIS) (n = 12) or invasive cancer (n = 1). Good to excellent cosmetic results were achieved for 21 patients (95.5%). Complications occurred for six patients (26.1%), including three patients with ischemia of the reconstructed NAC.
The single-stage operation described in this report can allow patients with cancers abutting the NAC to consider BCT. This technique allows patients to avoid mastectomy and to minimize the number of operations required for reconstruction while maximizing cosmetic outcomes. In the study cohort, the presence of extensive DCIS resulted in a significant need for reexcision, which could be performed successfully without compromise to cosmetic outcome.
We have no disclosures.
- 2.Van Dongen J, Bartelink H, Fentiman I, et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer: EORTC 10801 trial. Monogr Natl Cancer Inst. 1992;11:8–15.Google Scholar
- 9.Fisher ER, Gregorio R, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4) I: observations concerning the multicentricity of mammary cancer. Cancer. 1975;35247–54.Google Scholar
- 15.Danoff B, Pajak T, Solin L, et al. Excisional biopsy, axillary node dissection, and definitive radiotherapy for stages 1 and 2 breast cancer. Int J Radiat Oncol Biol Phys. 1985;11479–83.Google Scholar
- 25.Campbell EJ, Romics L. Oncological safety and cosmetic outcomes in oncoplastic breast conservation surgery: a review of the best level of evidence literature. Breast Cancer Targets Ther. 2017;9 521–30.Google Scholar
- 26.Chatterjee A, Gass J, Krishnabhai P, et al. A consensus definition and classification system of oncoplastic surgery developed by the American Society of Breast Surgeons. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-07345-4.
- 27.Crown A, Scovel LG, Rocha FG, et al. Oncoplastic breast-conserving surgery is associated with a lower rate of surgical-site complications compared to standard breast conserving surgery. Am J Surg. 2019;217:138–41.Google Scholar
- 34.Yun IS, Lew DH, Tark KC, et al. Nipple reconstruction with modified C–V flap:C–U flap. J Korean Soc Aesth Plast Surg. 2008;14:75–8.Google Scholar
- 35.Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on margin for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol. 2014;21:704–16.CrossRefGoogle Scholar
- 36.Ganz PA, Cecchini RS, White JR, et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. J Clin Oncol. 2019;37:508.CrossRefGoogle Scholar
- 43.Sanchez C, Brem RF, McSwain AP, et al. Factors associated with reexcision in patients with early-stage breast cancer treated with breast conservation surgery. Am Surg. 2010;76:331–4.Google Scholar
- 45.Fayanju OM, Ren Yi, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018;268:591–601.Google Scholar
- 46.Boughey JC, Peintinger F, Meric-Bernstam F, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006;244:464–70.Google Scholar
- 48.Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260:608–14; (discussion 614–6).Google Scholar
- 54.Huang J, Barbara L, BNrouwers M, et al. Does delay in starting treatment affect outcomes of radiotherapy? A systematic review. J Clin Oncol. 2003;21:555–63.Google Scholar
- 55.Punglia RS, Saito AM, Neville BA, et al. Impact of interval from breast conserving surgery to radiotherapy on local recurrence in older women with breast cancer: retrospective cohort analysis. BMJ. 2010;340:c845.Google Scholar